In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan NV

www.mylan.com

Latest From Mylan NV

Lupin Results Fail To Cheer But Signal Stabilization Of US Generic Market

Lupin’s management refer to multiple indicators suggesting the US generics segment is stabilizing. But traction for some key launches, delivering on pipeline promise, including in the inhalation space, and resolution of compliance issues could hold the key to lifting investor sentiment.

Commercial Strategy

Talks Must Start Now On New Irish Drug Supply Pact

An industry group representing Ireland’s generic-and-biosimilar makers says talks “need to start now” on a new national medicine supply accord to create more affordable access to life-saving drugs, with the association’s members at the negotiating table.

Ireland Regulation

Lupin Q4 Fails To Cheer But Signals Stabilization Of US Generic Market

Lupin’s management refer to multiple indicators suggesting the US generics segment is stabilizing. But traction for some key launches, delivering on pipeline promise, including in the inhalation space, and resolution of compliance issues could hold the key to lifting investor sentiment.

Commercial Strategy

BI Bags Third Place For Humira Biosimilar in US With AbbVie Pact

Boehringer Ingelheim has settled litigation with AbbVie over Humira by striking a deal that allows it to launch its biosimilar adalimumab in the US from the start of July 2023.

Biosimilars Legal Issues
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register